About: Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 1996

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 1996 (uk) article scientifique publié en 1996 (fr) im Juni 1996 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunu de 1996 (ast) scientific article published on 01 June 1996 (en)
publication date	wds:Q71102203-5CC4550B-C261-40A2-9197-D6CDE03CD9DE
publication date	1996-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q71102203-B3C87904-D30E-4316-9960-8CF0B4242AD1
language of work or name	English
cites work	wds:Q71102203-219E0289-3348-434B-80CA-379EF1F91F89 wds:Q71102203-24EB27E3-B37D-4436-A54F-6BE54DE0A36F wds:Q71102203-36AE403C-0044-45B1-A94C-FBA61F699376 wds:Q71102203-7AE591D0-4E1C-4791-885E-26279BA9D7C3 wds:Q71102203-8600B6E9-D868-4BA5-8E4C-26CDA9B2B494 wds:Q71102203-872D6EB6-046F-4501-B8A3-764AA9D4786A wds:Q71102203-8AC943C7-CE9A-4A39-A630-FAC8CEA198B5 wds:Q71102203-A5E802D6-2F23-47A2-A467-9248CD4DEBF7 wds:Q71102203-A7125070-FB7E-420B-AFBE-441A26BE2032 wds:Q71102203-B2ABCB3C-21AF-4548-BD5F-8EE18E8B19B0 wds:Q71102203-B573E19E-7789-4F8C-8C11-69ACE97F790A wds:Q71102203-BEA83370-CEE7-43EB-8F2F-50408F0A0817 wds:Q71102203-C7AD6F1C-9F65-4785-91E1-5E1654D470FA wds:Q71102203-D3A7C4A0-6926-4BCE-BCFB-4B49F6855506 wds:Q71102203-DAF3A80F-1FCD-4510-95F4-FD9B232ABB0E wds:Q71102203-EB2AC3A1-791C-4B5E-92F6-840E2C8C279A wds:Q71102203-F11FCBF6-6D8E-4227-8A5B-B685588FC559 wds:Q71102203-F538715F-E551-4AD5-B670-DBB5F841166E wds:Q71102203-F6646D73-5289-4C46-8384-F36548F2E2BD wds:Q71102203-F6AD0511-A6FC-4946-A076-ABC24DF7C0E0
cites work	Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland Cancer statistics, 1995. Progestin therapy in advanced breast cancer: megestrol acetate--an evaluation of 160 treated cases Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen Specificity of Low Dose Fadrozole Hydrochloride (CGS 16949A) as an Aromatase Inhibitor Current status of endocrine treatment of carcinoma of the breast Suppression of estrogens with Aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: A review Phase II evaluation of megestrol acetate in previously treated patients with advanced breast cancer: relationship of response to previous treatment Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer Aromatase inhibition by delta 1-testolactone does not relieve the gonadotropin-induced late steroidogenic block in normal men First generation aromatase inhibitors--aminoglutethimide and testololactone
author name string	wds:Q71102203-0FB7FBB6-D116-4026-B787-77DDFC0F94FD wds:Q71102203-64C066AA-2CFE-4A4A-BB63-D8C30DD272B0 wds:Q71102203-723E5A71-1765-404A-AD69-DF8CCCA354D2 wds:Q71102203-739A9832-5519-47A5-BA70-B7573B858B3C wds:Q71102203-77FB990B-A3EA-48F3-8CEA-F2784823A80C wds:Q71102203-8156F611-9903-4DB5-9336-307F7C4406F0 wds:Q71102203-901113D1-8972-450D-B879-14947A8BEF32 wds:Q71102203-F541A7D4-AA2A-46E8-9035-887F5282BA38
author name string	Smith R Cooper J Buzdar AU Vogel C Bonomi P Favis G Keller AM Mulagha M
rdfs:label	Fadrozole HCL (nl) Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials (en)
skos:prefLabel	Fadrozole HCL (nl) Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials (en)
name	Fadrozole HCL (nl) Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials (en)
title	wds:Q71102203-C6451931-E17B-454A-91B5-A24C70EE6187
title	Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials (en)
page(s)	wds:Q71102203-CDF81979-A847-4D2D-AA5D-E102EE787234
page(s)	2503-2513
instance of	wds:Q71102203-9147BC33-C9A2-4F76-8E08-288B33B0874B
instance of	scholarly article
main subject	wds:Q71102203-1E649A5A-F76E-4267-A6F4-AB4A852844DF wds:Q71102203-6B9EAB94-34D8-415C-B1BA-AB0FBA32F711
main subject	megestrol breast carcinoma
PubMed ID	wds:Q71102203-EA26C0EF-165F-44DE-841B-23E505CD788A
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8640699
PubMed ID	8640699
published in	wds:Q71102203-0926C66E-B66E-432C-A9BC-7452A63E2B8F
published in	Cancer
issue	wds:Q71102203-6AB5179E-56A2-4806-9BED-AA6BD854F55D
volume	wds:Q71102203-DD2FF27A-2584-4EC1-8B7B-5FB3BE73F88A
issue	12
volume	77
DOI	wds:Q71102203-DB708111-A439-4553-AC6B-78CAB8E45240
DOI	http://dx.doi.org/10.1002/(SICI)1097-0142(19960615)77:12%3C2503::AID-CNCR13%3E3.0.CO;2-W
DOI	10.1002/(SICI)1097-0142(19960615)77:12<2503::AID-CNCR13>3.0.CO;2-W
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71102203
is cites work of	Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Aromatase inhibitors and inactivators for breast cancer therapy Clinical pharmacokinetics of aromatase inhibitors and inactivators

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software